Cardiac PET: Real-world Applications Webinar Series

ASNC’s “Cardiac PET: Real-world Applications Webinar Series” examines how F-18-labeled radiopharmaceuticals are poised to transform the diagnosis and management of three patient populations for whom imaging with current tracers and methodologies has been challenging.

Each 30-minute webinar features experts highlighting opportunities that nuclear cardiologists soon will have to improve patient care by using F-18 tracers.
 

1. The Role of F-18-labeled Tracers in Women - Now available OnDemand
Moderator: Tim Bateman, MD

• Challenges for MPI in women: What do we know? – Viviany Taqueti, MD
• Performance of F-18 flurpiridaz in women – Stephen Horgan, MD, MPH
  

2. The Role of F-18-labeled Tracers in Obese Patients - Now available OnDemand
Moderator: Gary Heller, MD, PhD

• Challenges for MPI with obese patients – Panithaya Chareonthaitawee, MD
• Performance of F-18 flurpiridaz in obese patients – Timothy Bateman, MD

3. The Role of F-18-labeled Tracers in Patients with Diabetes - Now available OnDemand
Moderator: Jamshid Maddahi, MD

• Worldwide epidemic of diabetes: Implications for coronary disease testing – Mouaz Al-Mallah, MD
• Performance of F-18 flurpiridaz in patients with diabetes – Rene Packard, MD

Credits

Attendees can earn up to 1.5 CME credits (0.5 per webinar).

Learning Objectives 

• Understanding the added value of PET MPI and MBF over SPECT in obese patients, patients with diabetes, and women at risk for cardiovascular disease
• Describing the significance of F-18 labeled tracers and what they offer over SPECT imaging and other PET MPI tracers in the target populations
• Analyzing recent clinical data with F-18 flurpiridaz and its potential impact on imaging women, obese patients, and women with suspected CAD.
• Reviewing clinical case studies demonstrating the enhanced image quality of F-18 flurpiridaz and diagnostic accuracy compared with SPECT imaging